Toresson L, Steiner J M, Spodsberg E, Olmedal G, Suchodolski J S, Lidbury J A, Spillmann T
Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, Helsinki University, Agnes Sjobergin katu 2, 00014 Helsinki, Finland; Evidensia Specialist Animal Hospital, Bergavagen 3, 25466 Helsingborg, Sweden.
Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, 4474 TAMU, College Station, TX 77843-4474, USA.
Vet J. 2019 Jan;243:8-14. doi: 10.1016/j.tvjl.2018.11.004. Epub 2018 Nov 12.
The objective of this study was to compare the effects of parenteral (PE) versus oral (PO) cobalamin supplementation on serum methylmalonic acid (MMA) and homocysteine (HCY) concentrations in dogs with hypocobalaminaemia. Thirty-six dogs with serum cobalamin concentrations below 285ng/L (reference interval (RI): 244-959ng/L) were treated with PO (0.25-1.0mg daily) or PE cobalamin (0.25-1.2mg/injection) using a block-randomized schedule. Serum MMA and HCY concentrations were analysed at day 0, 28 and 90 after start of supplementation. There was no significant difference between the PO and PE group regarding serum MMA or HCY concentrations at any time point. Median (range, P comparing baseline and 28 days, P comparing 28days and 90 days) serum MMA concentrations (nmol/L; RI 415-1193) were 932 (566-2468) in the PO and 943 (508-1900) in the PE group at baseline, respectively, 705 (386-1465, P<0.0001) and 696 (377-932, P<0.0001) after 28 days, and 739 (450-1221, P=0.58) and 690 (349-1145, P=0.76) after 90 days. Serum HCY concentrations (median (range), P comparing baseline and 28 days, P comparing 28days and 90 days, μmol/L; RI 5.9-31.9) in the PO and PE groups were 12.2 (3.3-62.2) and 8.4 (3.7-34.8) at baseline, 12.5 (5.0-45.0, P=0.61) and 8.0 (3.8-18.3, P=0.28) after 28 days, and 17.7 (7.3-60.0 P=0.07) and 12.4 (6.3-33.1, P=0.0007) after 90 days, respectively. Oral and parenteral cobalamin supplementation had the same effect on serum MMA concentrations in this group of dogs.
本研究的目的是比较肠胃外(PE)与口服(PO)补充钴胺素对钴胺素血症犬血清甲基丙二酸(MMA)和同型半胱氨酸(HCY)浓度的影响。36只血清钴胺素浓度低于285ng/L(参考区间(RI):244 - 959ng/L)的犬,采用区组随机设计,分别接受PO(每日0.25 - 1.0mg)或PE钴胺素(每次注射0.25 - 1.2mg)治疗。在开始补充后的第0、28和90天分析血清MMA和HCY浓度。在任何时间点,PO组和PE组之间的血清MMA或HCY浓度均无显著差异。PO组和PE组血清MMA浓度(中位数(范围),比较基线与28天、28天与90天的P值,nmol/L;RI 415 - 1193)在基线时分别为932(566 - 2468)和943(508 - 1900),28天后分别为705(386 - 1465,P<0.0001)和696(377 - 932,P<0.0001),90天后分别为739(450 - 1221,P = 0.58)和690(349 - 1145,P = 0.76)。PO组和PE组血清HCY浓度(中位数(范围),比较基线与28天、28天与90天的P值,μmol/L;RI 5.9 - 31.9)在基线时分别为12.2(3.3 - 62.2)和8.4(3.7 - 34.8),28天后分别为12.5(5.0 - 45.0,P = 0.61)和8.0(3.8 - 18.3,P = 0.28),90天后分别为17.7(7.3 - 60.0,P = 0.)和12.4(6.3 - 33.1,P = 0.0007)。在这组犬中,口服和肠胃外补充钴胺素对血清MMA浓度的影响相同。